Unilever and Reckitt in contest for Kodak arm
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.TWO UK firms, Unilever and Reckitt & Colman, are said to be among the three final bidders in Kodak's private auction of its household products division, whose price could now reach dollars 2bn.
A buyer could be announced later this week, according to industry analysts who have followed the three-month bidding process for L&F. Since Kodak announced plans in May to divest non-core businesses, a dozen consumer products companies have expressed interest in the unit, which encompasses a diverse range of brands led by Lysol, the best-selling line of disinfectant cleaners and deodorisers.
Kodak is believed to have decided to sell the unit whole to a single buyer, which is expected to re-sell some of its brands to recoup some of the cost.
The anticipated price-tag for L&F has soared to between dollars 1.7bn and dollars 2bn because of the keen interest in Lysol, squeezing smaller prospective buyers and leaving only the two big European firms and a third reported bidder, Colgate-Palmolive, in the running. The weak US dollar has considerably strengthened the buying power of non-American bidders.
Kodak yesterday confirmed that it expects easily to recoup the dollars 5.4bn book value of the four businesses it is selling as part of the refocusing announced last spring. It has already raised dollars 1.68bn from the sale of the prescription drugs division of Sterling Winthrop to France's Sanofi.
Either Bayer AG or Procter & Gamble is expected to pay another dollars 2bn for the over-the-counter division of the drug company. The fourth business on the block is Kodak's clinical diagnostics division.
Market Report, page 24
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments